Patents by Inventor Peter Carmeliet

Peter Carmeliet has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20040248796
    Abstract: The present invention provides materials and methods for VEGF-B and PDGF therapy, especially therapy directed at stem cell recruitment, proliferation, and/or differentiation.
    Type: Application
    Filed: February 4, 2004
    Publication date: December 9, 2004
    Inventors: Kari Alitalo, Ulf Eriksson, Peter Carmeliet, Xuri Li, Desire Collen, Seppo Yla-Herttuala, Petri Salven, Iiro Rajantie
  • Publication number: 20040053837
    Abstract: A method for modulating vasculogenesis or arteriogenesis or angiogenesis, especially for treating heart and limb ischemia, using the core domain protein of PDGF-C, a new member of the PDGF/VEGF family of growth factors, or a homodimer or a heterodimer comprising the core domain. Also disclosed are pharmaceutical compositions comprising the core protein, nucleotide sequences encoding the protein, and uses thereof in medical and diagnostic applications.
    Type: Application
    Filed: May 16, 2003
    Publication date: March 18, 2004
    Applicant: Ludwig Institute for Cancer Research
    Inventors: Xuri Li, Ulf Eriksson, Peter Carmeliet, Desire?apos; Collen
  • Publication number: 20030211994
    Abstract: A method for modulating vasculogenesis or angiogenesis using the core domain protein of PDGF-C, a new member of the PDGF/VEGF family of growth factors, or a homodimer or a heterodimer comprising the core domain. Also disclosed are pharmaceutical compositions comprising the core protein, nucleotide sequences encoding the protein, and uses thereof in medical and diagnostic applications.
    Type: Application
    Filed: November 26, 2002
    Publication date: November 13, 2003
    Applicant: Ludwig Institute for Cancer Research
    Inventors: Xuri Li, Ulf Eriksson, Peter Carmeliet, Desire Collen
  • Publication number: 20030180286
    Abstract: The present invention relates to the field of pathological angiogenesis and arteriogenesis. in particular, a stress induced phenotype in a transgenic mouse (PIGF−/−) that does not produce Placental Growth Factor (PIGF) and that demonstrates an impaired vascular endothelial growth factor (VEGF)-dependent response. PIGF-deficiency has a negative influence on diverse pathological processes of angiogenesis, arteriogenesis and vascular leakage comprising ischemic retinopathy, tumour formation, pulmonary hypertension, vascular leakage (oedema formation) and inflammatory disorders. Molecules that can inhibit the binding of PIGF to its receptor (VEGFR-1), such as monoclonal antibodies and tetrameric peptides. Further, the use of these molecules to treat the latter pathological processes.
    Type: Application
    Filed: November 11, 2002
    Publication date: September 25, 2003
    Inventors: Peter Carmeliet, Desire Collen, Sandro De Falco, Ruvo Menotti
  • Publication number: 20030144237
    Abstract: An antagonist to the activator of the Rse and Mer receptor protein tyrosine kinases, encoded by growth arrest-specific gene 6 (gas6), is found to be useful in a method of treating an insulin-resistant disorder such as diabetes. More particularly, a method for treating an insulin-resistant disorder is provided which comprises administering to a mammal in need of such treatment an effective amount of a composition comprising a gas6 antagonist. A hypoglycemic agent may be co-administered with the gas6 antagonist.
    Type: Application
    Filed: October 8, 2002
    Publication date: July 31, 2003
    Inventors: Peter Carmeliet, Desire Collen, Anne Angelillo-Scherrer
  • Publication number: 20030125233
    Abstract: The present invention relates to methods of treatment and/or prevention of pulmonary hypertension and to methods of treatment and/or prevention of cardiac remodelling and more specifically to cardiac remodelling induced by systemic hypertension in a mammal, particularly a human being. In particular, the invention shows a novel, negative role for urokinase-type plasminogen activator in the pathogenesis of cardiac remodelling, leading to subsequent cardiac dysfunction, and in the pathogenesis of pulmonary hypertension usually complicated by subsequent right ventricular hypertrophy. Consequently, the use of selective inhibitors of u-PA activity can be of benefit for treatment of patients suffering from pulmonary hypertension and/or cardiac remodelling.
    Type: Application
    Filed: December 23, 2002
    Publication date: July 3, 2003
    Inventors: Peter Carmeliet, Desire Collen, Stephane Heymans, Marcel Levi
  • Publication number: 20030105018
    Abstract: The present invention relates to neurological and physiological dysfunction associated with neuron disorders. In (particular, the invention relates to the involvement of vascular endothelial growth factor (VEGF) and homologues in the aetiology of motor neuron disorders. The invention further concerns a novel, mutant transgenic mouse (VEGFm/m) with a homozygous deletion in the hypoxia responsive element (HRE) of the VEGF promoter which alters the hypoxic upregulation of VEGF. These mice suffer severe adult onset muscle weakness due to progressive spinal motor neuron degeneration which is reminiscent of amyotrophic lateral sclerosis (ALS)—a fatal disorder with unknown aetiology. Furthermore, the neuropathy of these mice is not caused by vascular defects, but is due to defective VEGF-mediated survival signals to motor neurons.
    Type: Application
    Filed: October 10, 2002
    Publication date: June 5, 2003
    Inventors: Peter Carmeliet, Desire Collen, Bert Oosthuyse
  • Publication number: 20030054995
    Abstract: Vascular endothelial growth factor, placenta growth factor or combinations of both including heteodimers are useful in the treatment or prevention of stroke or ischemic diseases in mammals.
    Type: Application
    Filed: September 23, 2002
    Publication date: March 20, 2003
    Inventor: Peter Carmeliet
  • Publication number: 20030008824
    Abstract: VEGF-B is shown to be needed for cardiac muscle revascularization after heart infarction, and methods of promoting or stimulating vascular development, e.g. angiogenesis and/or arteriogenesis, particularly in ischemic mammals, are disclosed.
    Type: Application
    Filed: June 20, 2002
    Publication date: January 9, 2003
    Applicant: Ludwig Institute for Cancer Research
    Inventors: Ulf Eriksson, Xuri Li, Peter Carmeliet, Desire Collen